EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

Core Viewpoint - The comparison between Exelixis (EXEL) and Incyte (INCY) indicates that EXEL is currently more attractive to value investors due to its stronger earnings estimate revisions and more favorable valuation metrics [3][7]. Valuation Metrics - EXEL has a forward P/E ratio of 17.53, significantly lower than INCY's forward P/E of 53.46 [5]. - EXEL's PEG ratio stands at 0.74, while INCY's PEG ratio is 2, suggesting that EXEL is expected to grow at a more favorable rate relative to its price [5]. - The P/B ratio for EXEL is 4.24, which is comparable to INCY's P/B of 4.25, indicating similar market value versus book value [6]. Analyst Outlook - EXEL holds a Zacks Rank of 2 (Buy), reflecting a more positive analyst outlook compared to INCY's Zacks Rank of 3 (Hold) [3]. - The stronger estimate revision activity for EXEL suggests a more favorable future performance as perceived by analysts [7]. Value Grades - EXEL has a Value grade of B, while INCY has a Value grade of C, further supporting the conclusion that EXEL is the superior option for value investors at this time [7].